Arovella Therapeutics Limited (ALA) Stock Statistics & Valuation Metrics

Arovella Therapeutics Limited has a market cap or net worth of AUD 61.05M. The enterprise value is AUD 60.24M.

Market Cap

AUD 61.05M

Enterprise Value

AUD 60.24M

Arovella Therapeutics Limited has 1,208,851,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,208,851,800

Owned by Insiders

0.28%

Owned by Institutions

―

Arovella Therapeutics Limited’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -52.55%.

Return on Equity (ROE)

-0.49

Return on Assets (ROA)

-0.46

Return on Invested Capital (ROIC)

-52.55%

Return on Capital Employed (ROCE)

-0.79

Revenue Per Employee

0

Profits Per Employee

-256.16K

Employee Count

27

Asset Turnover

0.00

Inventory Turnover

0.00

The current PE Ratio of Arovella Therapeutics Limited is -8.71. Arovella Therapeutics Limited’s PEG ratio is -0.64.

PE Ratio

-8.71

PS Ratio

0.00

PB Ratio

4.29

Price to FCF

-8.79

Price to Operating Cash Flow

-8.80

PEG Ratio

-0.64

In the last 12 months, Arovella Therapeutics Limited had revenue of 0 and earned -6.92M in profits. Earnings per share was -0.01.

Revenue

0

Gross Profit

-117.71K

Operating Income

-11.21M

Pretax Income

-10.41M

Net Income

-6.92M

EBITDA

-11.10M

Earnings Per Share (EPS)

-0.01

In the last 12 months, operating cash flow was -6.91M and capital expenditures -39,261, giving a free cash flow of -6.95M billion.

Operating Cash Flow

-6.91M

Free Cash Flow

-6.95M

Free Cash Flow per Share

-0.01

Arovella Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-11.49%

Earnings Yield

-11.50%

Beta

1.51

52-Week Price Change

-43.82%

50-Day Moving Average

0.05

200-Day Moving Average

0.07

Relative Strength Index (RSI)

38.92

Average Volume (3m)

715.04K

Arovella Therapeutics Limited upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date

Feb 19, 2026

Next Earnings Date

―

Ex-Dividend Date

―

Arovella Therapeutics Limited as a current ratio of 17.51, with Debt / Equity ratio of 0.00%

Current Ratio

17.51

Quick Ratio

17.51

Debt to Market Cap

0.00

Net Debt to EBITDA

1.29

Interest Coverage Ratio

0.00

In the past 12 months, Arovella Therapeutics Limited has paid -3.50M in taxes.

Income Tax

-3.50M

Effective Tax Rate

0.34

Arovella Therapeutics Limited EV to EBITDA ratio is -4.15, with an EV/FCF ratio of -6.64.

EV to Sales

0.00

EV to EBITDA

-4.15

EV to Free Cash Flow

-6.64

EV to Operating Cash Flow

-6.67

Arovella Therapeutics Limited has AUD 14.35M in cash and marketable securities with AUD 0.00 in debt, giving a net cash position of AUD 14.35M billion.

Cash & Marketable Securities

AUD 14.35M

Total Debt

AUD 0.00

Net Cash

AUD 14.35M

Net Cash Per Share

AUD 0.01

Tangible Book Value Per Share

AUD 0.01

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Arovella Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

-100.00%

EPS Growth Forecast

14.71%

Smart Score

7

AI Score

41